Camzyos recommended for NHS use in heart condition

6 September 2023
bristol_myers_squibb_shutterstock_large

The National Institute for Health and Care Excellence (NICE) has published Final Guidance on a new medicine for the treatment of the most common inherited heart condition in England and Wales.

Mavacamten—branded by US pharma major Bristol Myers Squibb (NYSE: BMY) as Camzyos—will now be available on the National Health Service (NHS) as a treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

The final guidance recommends this product in eligible patients as an add-on to individually optimised standard care, including beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical